Nuwellis (NASDAQ:NUWE) Releases Earnings Results, Beats Expectations By $0.06 EPS

Nuwellis (NASDAQ:NUWE) announced its earnings results on Tuesday. The company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.56) by $0.06, FiscalAI reports. The firm had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.31 million. Nuwellis had a negative return on equity of 1,367.63% and a negative net margin of 202.83%.

Here are the key takeaways from Nuwellis’ conference call:

• Company completed a transition to contract manufacturing with KDI Precision Manufacturing to improve supply reliability and long-term structural margins, prioritizing operational predictability over short-term cost cuts.
• Strategic refocus on the cardiorenal continuum—with emphasis on heart failure and pediatrics—was reinforced by expanded IP and a NIH grant supporting the pediatric device (Vivian), strengthening long-term differentiation.
• Management is integrating the Rendiatech acquisition (Clarity) to add bedside urine-output and analyte monitoring for ICU/critical-care patients, with a planned mid-year relaunch to drive deeper utilization in existing accounts.
• Financials show mixed trends: Q4 revenue rose to $2.4M and gross margin improved, but full-year revenue fell 5%, net loss was $17.5M (including a $6.4M non-cash warrant expense), and year-end cash was only about $1.2M after ~$10.9M cash usage.
• Commercially, U.S. console sales jumped 208% in Q4 and the direct sales team is now 24 people focused on driving utilization in existing accounts (particularly critical care), with headcount expected to remain stable in 2026.

Nuwellis Stock Performance

NUWE stock traded up $0.05 during midday trading on Tuesday, reaching $1.34. 178,569 shares of the company’s stock traded hands, compared to its average volume of 2,830,714. Nuwellis has a 52 week low of $1.20 and a 52 week high of $53.34. The company has a 50-day moving average price of $2.17 and a two-hundred day moving average price of $2.87. The firm has a market capitalization of $2.50 million, a PE ratio of -0.01 and a beta of -0.03.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on NUWE shares. Wall Street Zen downgraded shares of Nuwellis from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.